1. Home
  2. ESTA vs PHVS Comparison

ESTA vs PHVS Comparison

Compare ESTA & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Establishment Labs Holdings Inc.

ESTA

Establishment Labs Holdings Inc.

HOLD

Current Price

$81.45

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$30.97

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESTA
PHVS
Founded
2004
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
ESTA
PHVS
Price
$81.45
$30.97
Analyst Decision
Strong Buy
Buy
Analyst Count
7
11
Target Price
$86.86
$41.82
AVG Volume (30 Days)
418.0K
333.2K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
42.67
N/A
EPS
N/A
N/A
Revenue
$61,208,000.00
N/A
Revenue This Year
$28.05
N/A
Revenue Next Year
$26.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
76.49
N/A
52 Week Low
$33.35
$16.00
52 Week High
$85.56
$33.33

Technical Indicators

Market Signals
Indicator
ESTA
PHVS
Relative Strength Index (RSI) 64.31 53.33
Support Level $63.71 $24.55
Resistance Level $83.31 $33.33
Average True Range (ATR) 4.78 1.42
MACD 1.12 0.11
Stochastic Oscillator 79.29 51.55

Price Performance

Historical Comparison
ESTA
PHVS

About ESTA Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: